Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2019
Event: Announcement of Nasdaq Capital Market listing approval.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a corporate governance event regarding stock listing status.
Material Changes
Listing Approval: The Company's common shares have been approved to list on the Nasdaq Capital Market.
Trading Commencement: Trading is expected to begin on August 14, 2019.
Trading Details: The stock will trade under the existing ticker symbol "NEPH" and CUSIP number 640671400.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the transition to the Nasdaq Capital Market but contains no forward-looking financial guidance, risk factors, or discussion of contingencies.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the commencement of trading on the Nasdaq Capital Market on August 14, 2019.
- Confirm the continued use of the ticker symbol "NEPH" and CUSIP 640671400.
- Review the attached press release (Exhibit 99.1) for additional context on the listing approval.